From: Effect of cachexia on bone turnover in cancer patients: a case-control study
All patients | Patients without bone metastases | |||||
---|---|---|---|---|---|---|
Cancer Cachexia (n = 31) |
Cancer (n = 21) | p | Cancer Cachexia (n = 28) |
Cancer (n = 16) | p | |
CTX, ng/mL | 0.38 (0.3–0.6) | 0.31 (0.2–0.4) | 0.08 | 0.38 (0.3–0.5) | 0.27 (0.2–0.4) | 0.03 |
Ocn ng/ml a | 14.2 (± 5.5) | 16.4 (± 5.3) | 0.2 | 14.3 (± 5.6) | 16.4 (± 4.4) | 0.2 |
CTX/Ocn ratio > 0.022, n (%) | 21 (67.7) | 6 (28.6) | 0.006 | 19 (67.9) | 3 (18.8) | 0.002 |
PINP, μg/L | 32 (23–39) | 27.5 (22–41) | 0.6 | 31.9 (23–38) | 26.1 (21–38) | 0.5 |
CTX/PINP ratio > 0.011, n (%) | 19 (61.3) | 8 (38.1) | 0,1 | 17 (60.7) | 5 (31.3) | 0.06 |
Corrected Ca, mmol/L | 2.45 (2.4–2.6) | 2.35 (2.3–2.4) | 0.002 | 2.43 (2.4–2.5) | 2.33 (2.3–2.4) | 0.001 |
Phosphate, mg/dL | 4.2 (4–4.4) | 4.3 (4.2–4.6) | 0.09 | 4.2 (4–4.4) | 4.4 (4.2–4.6) | 0.1 |
PTH, pg/mL | 24.1 (18–34) | 27 (23–32) | 0.5 | 24.4 (19–34) | 26.6 (23–32) | 0.7 |
25(OH)D, ng/mL | 14.4 (8–22) | 13 (8–21) | 0.7 | 15.1 (8–22) | 13 (9–21) | 0.8 |
TSH, μU/mL | 1.7 (1.2–3.4) | 1.3 (0.7–1.9) | 0.03 | 1.7 (1–3.3) | 1.2 (0.6–1.7) | 0.02 |